Association for Behavioral Health and Wellness Calls for Changes to Substance Abuse Privacy Laws | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

Association for Behavioral Health and Wellness Calls for Changes to Substance Abuse Privacy Laws

December 23, 2015
by Heather Landi
| Reprints

Privacy protections for alcohol and drug abuse patient records need to be changed to be in harmony with the Health Information Technology for Economic and Clinical Health (HITECH) Act and to enable better coordinated care, according to a paper released this week by the Association for Behavioral Health and Wellness (ABHW).

The paper, titled Now is the Time to Strengthen Protection of Substance Use Records by Revisiting the Substance Abuse Privacy Law, calls for changes to the Confidentiality of Alcohol and Drug Abuse Patient Records, 42 Code of Federal Regulations (CFR) Part 2 (Part 2). “Part 2 is an outdated federal regulation that hinders safe, effective, high quality substance use treatment,” the ABHW states.

The Part 2 regulations were originally authorized by the Comprehensive Alcohol Abuse and Alcoholism Prevention, Treatment and Rehabilitation Act of 1970 and Drug Abuse Prevention, Treatment and Rehabilitation Act of 1972. Part 2 sets out protections against unauthorized disclosure of substance abuse records as a way to encourage people to seek treatment.

In the paper, ABHW highlights that in the 40 years since the Part 2 regulations were created there have been huge changes in the organization and financing of substance use treatment. Patient centered medical homes that integrate medical and behavioral care are widely adopted and paper records have been largely replaced by electronic health records (EHRs).

“The use and exchange of health information, especially electronic health information, is governed by a comprehensive set of federal stringent privacy and security regulations that did not exist when the substance use record protections were enacted. The part 2 regulations were appropriate for a different time,” the ABHW report authors wrote. “The Part 2 provisions that now create obstacles to safe, quality care for people who have substance use disorders were developed for an earlier time, and not required by law.”

In May 2014, the Substance Abuse and Mental Health Services Administration (SAMHSA) stated that “behavioral health is essential to overall health and the costs of untreated substance abuse disorders, both personal and societal, are enormous.

”SAMHSA expressed an interest in examining the burden associated with specific consent requirements that don’t necessarily protect privacy and may be a barrier to coordinated care.

A proposed rule revising Part 2 is currently under review by the Office of Management and Budget (OMB).

“ABHW hopes that the proposed rule will be released shortly and will bring substance use privacy protections into harmony with the Health Insurance Portability and Accountability Act (HIPAA), the Affordable Care Act (ACA), and the HITECH Act. Separation of substance use from the rest of medicine creates several problems: primary care lacks the ability to coordinate a patient’s medical and substance use treatment; substance use treatment programs lack the capability to coordinate a patient’s medical and substance use care; and, patients are put at risk of unsafe, uncoordinated and uninformed care,” Pamela Greenberg, ABHW president and CEO, said.

ABHW’s paper proposes changes that can be made to Part 2 that balance the need to facilitate communications in support of safe, high quality health care with the need to protect the privacy interests of persons who seek treatment for substance use disorders.


Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.

Learn More



Nothing in 42CFR2 prohibits a person from disclosing information regarding their substance abuse treatment. The decision of what to disclose to whom is the patient's to make, period. Unless the authors want to argue that they somehow "know better" what is in the patient's interest, their entire argument falls apart. The regulations already contain provisions for disclosing information without consent under special conditions such as the declaration of a medical emergency or the commission of a crime at the treatment site.


Healthcare Execs Anticipate High Cost Returns from Predictive Analytics Use

Healthcare executives are dedicating budget to predictive analytics, and are forecasting significant cost savings in return, according to new research from the Illinois-based Society of Actuaries.

Adam Boehler Tapped by Azar to Serve as Senior Value-Based Care Advisor

Adam Boehler, currently director of CMMI, has also been named the senior advisor for value-based transformation and innovation, HHS Secretary Alex Azar announced.

Vivli Launches Clinical Research Data-Sharing Platform

On July 19 a new global data-sharing and analytics platform called Vivli was unveiled. The nonprofit group’s mission is to promote, coordinate and facilitate scientific sharing and reuse of clinical research data.

Survey: More Effective IT Needed to Improve Patient Safety

In a Health Catalyst survey, physicians, nurses and healthcare executives said ineffective information technology, and the lack of real-time warnings for possible harm events, are key obstacles to achieving their organizations' patient safety goals.

Physicians Still Reluctant to Embrace Virtual Tech, Survey Finds

While consumers and physicians agree that virtual healthcare holds great promise for transforming care delivery, physicians still remain reluctant to embrace the technologies, according to a new Deloitte Center for Health Solutions survey.

Geisinger, AstraZeneca Partner on Asthma App Suite

Geisinger has partnered with pharmaceutical company AstraZeneca to create a suite of products that integrate into the electronic health record and engage asthma patients and their providers in co-managing the disease.